The stock has dipped nearly 6% at Rs 364 in early morning deals on the Bombay Stock Exchange.
Ranbaxy Laboratories has dipped nearly 6% at Rs 364 in early morning deals on BSE after reporting a consolidated net loss of Rs 454 crore for the third quarter ended September 2013 (Q3) due to forex loss. The pharmaceutical company had profit of Rs 754 crore in a year ago quarter.
The company incurred a forex charge of Rs 360 crore during the reported quarter, against forex gain of Rs 393 crore in the same period last year, Ranbaxy said in a statement.
The consolidated net sales also grew marginally by 3% at Rs 2,750 crore against Rs 2,670 crore in the corresponding quarter of previous year.
The company said sale impacted by the new pricing policy and trade concerns in India and the absence of any post exclusively sales during the quarter.
The company incurred a forex charge of Rs 360 crore during the reported quarter, against forex gain of Rs 393 crore in the same period last year, Ranbaxy said in a statement.
The consolidated net sales also grew marginally by 3% at Rs 2,750 crore against Rs 2,670 crore in the corresponding quarter of previous year.
The company said sale impacted by the new pricing policy and trade concerns in India and the absence of any post exclusively sales during the quarter.
No comments:
Post a Comment